A recent study has revealed a significant gap between guidelines and clinical practice in the treatment of metastatic prostate cancer.
A survey of US-based physicians, published in JAMA Network Open, highlighted a concerning trend: many doctors are not prescribing optimal treatment intensification (TI) for patients with metastatic castration-sensitive prostate cancer (mCSPC). This is despite strong evidence from clinical trials demonstrating the benefits of TI in prolonging survival and improving quality of life.
Key findings from the study:
- Low Rates of Treatment Intensification: Only 30.3% of patients with mCSPC received TI as their first-line treatment.
- Physician Beliefs and Practices: Many doctors cited concerns about tolerability and a lack of understanding of guidelines as reasons for not prescribing TI.
- PSA Reduction Goals: Some doctors set overly conservative PSA reduction goals, potentially limiting the effectiveness of treatment.
Why is this a problem?
Treatment intensification, which involves adding additional therapies like androgen receptor pathway inhibitors (ARPIs) or chemotherapy to standard hormone therapy, has been proven to improve patient outcomes. By not prescribing TI, many doctors are missing an opportunity to extend patients’ lives and improve their quality of life.
What can be done to improve treatment rates?
“Physician education on treatment guidelines and clinical trial data, while raising expectations for PSA response, may increase rates of first-line TI in mCSPC.”
To address this issue, several strategies could be implemented:
- Enhanced Physician Education: Providing comprehensive education and training to physicians about the benefits, risks, and optimal use of TI can help to dispel misconceptions and improve prescribing practices.
- Clearer Guideline Development: Developing clear and concise guidelines can help to standardise treatment approaches and promote evidence-based practice.
- Patient Advocacy: Encouraging patients to actively engage in their care and discuss treatment options with their doctors can empower them to advocate for optimal treatment.
The authors urge that by addressing these factors, healthcare providers can work to ensure that more patients with mCSPC receive the appropriate treatment and experience better outcomes.
Paper: Agarwal NGeorge DJKlaassen Z, et al. Physician Reasons for or Against Treatment Intensification in Patients With Metastatic Prostate Cancer. JAMA Netw Open. 2024;7(12):e2448707. Access online here.
